加载中
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
前收盘价
US$1.27
−US$0.03 · -2.31%
盘中时间采用ET。市场数据可能有所延迟。
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
日内区间
当前US$1.27
52周区间
当前US$1.27
盘中时间采用ET。市场数据可能有所延迟。
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
日内区间
当前US$1.27
52周区间
当前US$1.27
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 4.6万 USD | — | — | — | 51.9万 USD |
| 毛利 | −4.6万 USD | — | — | — | −51.9万 USD |
| 研究与开发 | 1523.4万 USD | 1447.8万 USD | 1585.9万 USD | 835万 USD | 1890.3万 USD |
| 销售、一般及管理费用 | 788.7万 USD | 972.6万 USD | 2221.6万 USD | 584.3万 USD | 1704.4万 USD |
| 营业费用 | 2312.1万 USD | 2420.4万 USD | 3807.5万 USD | 1419.3万 USD | 3542.8万 USD |
| 利息收入 | 71.3万 USD | — | — | — | 12.6万 USD |
| 利息支出 | 142.2万 USD | — | 11万 USD | 13.2万 USD | 12.6万 USD |
| 折旧和摊销 | 4.6万 USD | 5.8万 USD | 5.8万 USD | 5.2万 USD | 51.9万 USD |
| 营业利润 | −2312.1万 USD | −2420.4万 USD | −3807.5万 USD | −1419.3万 USD | −3594.7万 USD |
| 净利润 | −2956.2万 USD | −1370万 USD | −3435.7万 USD | −782.4万 USD | −3582.1万 USD |
公司数据更新于 2026年10月11日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$266
上涨空间 20844.88%评级样本有限，仅3项
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年8月31日 | 1:5 | — | — |
股票拆分 | 2023年3月20日 | 1:14 | — | — |
已生效 2026年8月31日
1:5
已生效 2023年3月20日
1:14
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
